Edition:
United States

Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

37.04USD
5 Dec 2016
Change (% chg)

-- (--)
Prev Close
$37.04
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,693,123
52-wk High
$66.55
52-wk Low
$36.40

Summary

Name Age Since Current Position

Yitzhak Peterburg

65 2015 Chairman of the Board

Erez Vigodman

56 2014 President, Chief Executive Officer, Director

Eyal Desheh

63 2014 Group Executive Vice President, Chief Financial Officer

Carlo De Notaristefani

58 2012 President and Chief Executive Officer, Global Operations

Robert Koremans

54 2013 President, Chief Executive Officer - Global Specialty Medicines

Sigurdur Olafsson

47 2014 President and Chief Executive Officer - Global Generic Medicines Group

Iris Beck-Codner

50 2014 Group Executive Vice President - Corporate Marketing Excellence and Communication

Mark Sabag

45 2013 Group Executive Vice President, Human Resources

Timothy Wright

58 2015 Executive Vice President, Business Development, Strategy and Commercial Innovation

Michael Hayden

64 2012 President - Global Research and Development, Chief Scientific Officer

David Stark

2016 Chief Legal Officer

Roger Abravanel

70 2007 Director

Sol Barer

68 2015 Director

Arie Belldegrun

66 2013 Director

Rosemary Crane

56 2015 Director

Amir Elstein

60 2014 Director

Gerald Lieberman

68 2015 Director

Galia Maor

73 2012 Director

Ory Slonim

73 2008 Director

Jean-Michel Halfon

64 2014 Statutory - independent director

Joseph Nitzani

70 2008 Statutory Independent Director

Gabrielle Sulzberger

55 2015 Statutory Independent Director

Kevin Mannix

Vice President, Head of Investor Relations

Biographies

Name Description

Yitzhak Peterburg

Prof. Yitzhak Peterburg serves as Chairman of the Board at Teva Pharmaceutical Industries Limited since January 1, 2015. His work experience includes the following roles: Director at the Company (January 2012-January 1, 2015), Group Vice President—Global Branded Products at the Company (October 2010-October 2011), Director at the Company (2009-July 2010), President and Chief Executive Officer at Cellcom Israel Ltd. (2003-2005), Director General of Clalit Health Services (1997-2002), Chief Executive Officer at Soroka University Medical Center (1995-1997), Director at Rosetta Genomics Ltd. and Chairman at Regenera Pharma Ltd. Prof. Peterburg holds a Doctorate of Medicine degree from Hadassah Medical School in 1977 and is board-certified in Pediatrics and Health Services Management. He also holds a Doctorate in Philosophy degree in Health Administration from Columbia University and a Master of Science degree in Information Systems from London School of Economics. He is a Professor at the School of Business, Ben-Gurion University.

Erez Vigodman

Mr. Erez Vigodman serves as President, Chief Executive Officer and Director at Teva Pharmaceutical Industries Limited since February 11, 2014 after joining Teva’s Board of Directors in 2009. From 2010 to 2014, he served as President and Chief Executive Officer of Adama Agricultural Solutions Ltd. (formerly Makhteshim Agan Industries Ltd). From 2001 to 2009, he served as President and Chief Executive Officer of Strauss Group Ltd. Mr. Vigodman is a member of the Advisory Committee to the Israel National Economic Council and the International Advisory Board of the Israel Science Technology & Innovation Policy Institute. Mr. Vigodman received a Bachelors degree in Accounting and Economics from Tel Aviv University in 1987 and is a graduate of the program of Management Development at Harvard Graduate School of Business Administration. Mr. Vigodman is a certified public accountant.

Eyal Desheh

Mr. Eyal Desheh serves as Group Executive Vice President, Chief Financial Officer at Teva Pharmaceutical Industries Limited since 2012. He has served as Chief Financial Officer at the Company from July 2008 and as Interim President, Chief Executive Officer between October 30, 2013 and February 11, 2014. His work experience also includes the following roles: Executive Vice President and Chief Financial Officer at Check Point Software Technologies Ltd (2000-2008), Chief Financial Officer of Scitex Ltd (1996-2000) and Deputy Chief Financial Officer at Teva (1989-1996). He received a Bachelors degree in Economics in 1978 and a MBA degree, majoring in Finance, in 1981, both from The Hebrew University of Jerusalem.

Carlo De Notaristefani

Dr. Carlo De Notaristefani serves as President and Chief Executive Officer, Global Operations at Teva Pharmaceutical Industries Limited since 2012. His work experience includes the following roles: Member of the Senior Management team at Bristol-Myers Squibb, where he served as President Technical Operations and Global Support Functions, with responsibility for global supply chain operations, quality and compliance, procurement and information technology (2004-2011) and Senior positions holder of increasing responsibility in the areas of global operations and supply chain management at Aventis, Hoechst Marion Roussell and Marion Merrell Dow. Dr. De Notaristefani holds a Doctorate of Science degree in Chemical Engineering from University of Naples.

Robert Koremans

Dr. Robert (Rob) Koremans serves as President, Chief Executive Officer - Global Specialty Medicines at Teva Pharmaceutical Industries Limited since 2013. Prior to this role, he served as President and Chief Executive Officer at Teva Pharmaceuticals Europe from March 2012. His work experience includes the following roles: Member of the Global Leadership Team of Sanofi, Chief Executive Officer at Zentiva, Senior Vice President Generics, Strategy and Development at Sanofi, Chief Executive Officer at Cryo-Save, Member of the Executive Board in charge of Global Commercial Operations at Grunenthal GmbH and Vice President Europe, Middle-East and Africa at Serono. Dr. Koremans holds a Doctorate of Medicine degree from Erasmus University of Rotterdam.

Sigurdur Olafsson

Mr. Sigurdur Oli (Siggi) Olafsson serves as President and Chief Executive Officer - Global Generic Medicines Group at Teva Pharmaceutical Industries Limited since 2014. His work experience includes the following roles: President of Actavis Pharma (2012-2014), Executive Vice President-Global Generics at Actavis plc (Watson) (2010-2012), Chief Executive Officer at Actavis Group (2008-2010), Deputy Chief Executive Officer, Vice President of Corporate Development and Chief Executive Officer of Actavis Inc. US, Employee at Pfizer’s Global R&D organization in the UK and in the US (1998-2003) and Head of Drug Development at Omega Farma in Iceland (1994-1998). Mr. Olafsson holds a Master of Science degree in Pharmacy (Cand Pharm) from University of Iceland, Reykjavik.

Iris Beck-Codner

Ms. Iris Beck-Codner serves as Group Executive Vice President - Corporate Marketing Excellence and Communication at Teva Pharmaceutical Industries Limited since 2014. From 2013 to 2014, she served as Senior Vice President, Chief Communications Officer at the Company. From 2009 to 2012, she served as Group Chief Executive Officer of McCann Erickson Israel, IPG and from 2002 to 2008, as Vice President Marketing and Content at Partner Communications Company Ltd. From 1999 to 2000, she served as General Manager of Lever Israel, a wholly-owned subsidiary of Unilever Israel. Ms. Beck-Codner received a Bachelor of Arts degree in Economic Sciences from Haifa University and a MBA degree from Bar-Ilan University.

Mark Sabag

Mr. Mark Sabag serves as Group Executive Vice President-Human Resources at Teva Pharmaceutical Industries Limited since August 2013. His work experience at the Company includes the following roles: Global Deputy Vice President-Human Resources (2012-2013), Vice President-Human Resources at Teva’s International Group (2010-2012) and Vice President-Human Resources International Group and Corporate Human Capital (2006-2010). Prior to joining Teva, he held Senior Human Resources Roles at Intel Corporation. Mr. Sabag holds a Bachelors degree in Economics and Business Management from Haifa University.

Timothy Wright

Mr. Timothy (Tim) R. Wright serves as Executive Vice President, Business Development, Strategy and Commercial Innovation at Teva Pharmaceutical Industries Limited since April 13, 2015. His work experience includes the following roles: Founder and Chairman of the Drug Discovery and Development Institute for The Ohio State University Comprehensive Cancer Center and served as Director there (2011-2015), Member of the Ohio State Innovation Foundation Board and the Ohio State School of Pharmacy External Advisory Board, President at Covidien Pharmaceuticals (2007-2010), Interim Chief Executive Officer, President, Member of the Board of Directors and Chief Operating Officer at AAI Pharmaceuticals/Xanodyne (2004-2007), President-Global Operations at Elan Bio-Pharmaceuticals (2001-2004), President-Europe, Japan & ROW and Executive Vice President-Business Development & Licensing at Elan Bio-Pharmaceuticals (2001-2002), Senior Vice President, Strategy & Corporate Business Development at DuPont Merck Pharmaceutical Company (1996-1999), Vice President, Strategic Marketing & Operations-Europe at DuPont Merck Pharmaceutical Company (1995-1996), President & CEO, Toronto at DuPont Merck Pharmaceutical Company (1993-1995) and Vice President-Marketing at DuPont Merck Pharmaceutical Company (1990-1993). Mr. Wright holds a Bachelor of Science degree from Ohio State University.

Michael Hayden

Dr. Michael R. Hayden serves as President - Global Research and Development, Chief Scientific Officer at Teva Pharmaceutical Industries Limited since May 8, 2012. His work experience includes the following roles: Killam Professor of Medical Genetics at the University of British Columbia, Canada Research Chair in Human Genetics and Molecular Medicine, Founder and Senior Scientist of the Centre for Molecular Medicine and Therapeutics at the University of British Columbia, Founder of three biotechnology companies (NeuroVir, Aspreva Pharmaceuticals and Xenon Pharmaceuticals Inc.), Chief Scientific Officer at Xenon (2000-2012) and Director at Med Biogene Inc. (2010-2011). He has received numerous awards, including the Canada Gairdner Wightman Award in 2011, the Order of Canada Award in 2010, the highest honor that Canada can give its citizens for exceptional achievement and the Distinguished Scientist Award of the Canadian Society of Clinical Investigation in 1998 and he was named Canada’s Health Researcher of the Year in 2008. Dr. Hayden received a MB ChB in Medicine (a Bachelor of Medicine, Bachelor of Surgery degree) in 1975, a Doctorate of Science degree in Genetics in 1979 and a Diploma in Child Health (DCH) in 1979 from the University of Cape Town. He received his American Board Certification in both Internal Medicine and Clinical Genetics from Harvard Medical School in 1982 and a Fellow of the Royal College of Physicians of Canada (FRCPC) in Internal Medicine from University of British Columbia in 1984.

David Stark

Mr. David Stark serves as Chief Legal Officer of the Company. David Stark has amassed over 20 years of legal experience beginning with a series of New York law firms followed by a distinguished career at Teva. Since joining Teva in 2002, Mr. Stark served in a series of roles of increased responsibility in Teva North America and Teva Americas between 2002 and 2013, including Senior Director, Deputy General Counsel, and Vice President and General Counsel. In 2013 he was appointed Senior Vice President and General Counsel, Global Specialty Medicines, adding the position of Deputy Chief Legal Officer in 2016. Between 2014 and 2015 he also served as Acting Chief Legal Officer. Prior to joining Teva, Mr. Stark served as an associate in the litigation departments of Haight, Gardner, Poor & Havens (1994-1997), Chadbourne & Parke (1997-1998), and Willkie Farr & Gallagher (1998-2002).

Roger Abravanel

Mr. Roger Abravanel serves as Director at Teva Pharmaceutical Industries Limited since January 2007. His work experience includes the following roles: A Principal at McKinsey & Company (which he joined in 1972), Director at McKinsey & Company, Provider of Consulting services to Israeli and Italian private and venture capital funds, Director of COFIDE—Gruppo De Benedetti SpA (2008-2013), Director at Luxottica Group SpA (2006-2014), Director at Admiral Group plc, Director at Banca Nazionale del Lavoro (a subsidiary of BNP Paribas) and Chairman of INSEAD’s Advisory Group in Italy. Mr. Abravanel holds a Bachelor of Science degree in Chemical Engineering from Politecnico di Milano and a MBA degree from INSEAD.

Sol Barer

Dr. Sol J. Barer serves as Director at Teva Pharmaceutical Industries Limited since January 1, 2015. His work experience includes the following roles: Managing Partner at SJ Barer Consulting, has held top leadership roles at Celgene Corporation (1987-2011) including Executive Chairman (2010-2011), Chairman and Chief Executive Officer (2007-2010), Chief Executive Officer (2006-2010), President and Chief Operating Officer (1994-2006) and President (1993-1994), Founder of the biotechnology group at the chemical company Celanese Corporation (which was later spun off as Celgene), Director at Amicus Therapeutics and Aegerion Pharmaceuticals and Chairman of the Board of InspireMD and Medgenics. Dr. Barer holds a Doctorate of Science degree in Organic and Physical Chemistry from Rutgers, The State University of New Jersey and a Bachelor of Science degree in Chemistry from City University of New York at Brooklyn College.

Arie Belldegrun

Dr. Arie S. Belldegrun serves as Director at Teva Pharmaceutical Industries Limited since 2013. His work experience includes the following roles: Director of the Institute of Urologic Oncology and Professor and Chief of Urologic Oncology at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA), where he has held the Roy and Carol Doumani Chair in Urologic Oncology since 2000, Chairman, President, Chief Executive Officer and Founder of Kite Pharma, Inc., Chairman of Arno Therapeutics, Inc., Chairman of TheraCoat Ltd., Director at SonaCare Medical LLC, Director at Nile Therapeutics Inc. (until 2013), Founder and Founding Chairman of Agensys, Inc., Co-Founder and Founding Vice Chairman of the Board and Chairman of the Scientific Advisory Board at Cougar Biotechnology (which was acquired by Johnson & Johnson in 2009), Chairman and Partner of Two River Consulting, LLC., Chairman of the Molecular and Biological Technology Committee of the American Urological Association and Member of its Technology Assessment Council, Member of the Governor’s Council on Bioscience for the State of California; biotechnology Group Leader of the Mayor of Los Angeles’ Economy and Jobs Committee and Author of more than 450 scientific publications. Dr. Belldegrun holds a Doctorate of Medicine degree in Medicine from The Hebrew University of Jerusalem-Hadassah Medical School. He conducted his post-doctoral studies in Immunology at the Weizmann Institute of Science in Israel. He completed his Urologic Surgery Residency at Harvard Medical School and his fellowship at the National Cancer Institute/National Institutes of Health.

Rosemary Crane

Ms. Rosemary A. Crane serves as Director at Teva Pharmaceutical Industries Limited since September 2015. Her work experience includes the following roles: President and Chief Executive Officer of MELA Sciences, Inc. (2013-2014), Head of Commercialization and Partner at Appletree Partners (2011-2013), President and Chief Executive Officer of Epocrates Inc. (2008-2011), Group Chairman, OTC & Nutritional Group at Johnson & Johnson (2006-2008), Group Chairman, Consumer, Specialty Pharmaceuticals and Nutritionals at Johnson & Johnson (2004-2006), Executive Vice President of Global Marketing for the Pharmaceutical Group at Johnson & Johnson (2002-2004), President of U.S. Primary Care at Bristol-Myers Squibb (2000-2002), President of Global Marketing and Consumer Products at Bristol-Myers Squibb (1998-2000), Vice Chairman of the Board of Zealand Pharma A/S (since 2015). She holds a Bachelor of Arts degree in Communications and English from State University of New York and a MBA degree from Kent State University.

Amir Elstein

Mr. Amir Elstein serves as Director at Teva Pharmaceutical Industries Limited since January 2009. His work experience includes the following roles: Vice Chairman of the Board of Directors of Teva (January 2014-July 2014), Independent Director at the Company (January 2009-January 2014), Executive Vice President - Global Pharmaceutical Resources at the Company (March 2007-January 2009), Director at the Company (1995-2004), Chairman of the Board of Tower Semiconductor Ltd., Chairman of the Board of Governors of the Jerusalem College of Engineering, Chairman of the Board of the Israel Democracy Institute, Chairman and/or as a member of the board of directors of several academic, scientific, educational, social and cultural institutions, Chairman of the Board of Directors of Israel Corporation (2010-2013), General Manager of Intel Electronics Ltd. (subsidiary of Intel Corporation). He holds a Bachelor of Science degree in Physics and Math, a Master of Science degree in Solid State Physics and a Diploma of Senior Business Management, all from The Hebrew University of Jerusalem.

Gerald Lieberman

Mr. Gerald M. Lieberman serves as Director at Teva Pharmaceutical Industries Limited since September 2015. His work experience includes the following roles: Special Advisor at Reverence Capital Partners, President and Chief Operating Officer at AllianceBernstein L.P. (2004-2009), Chief Operating Officer at AllianceBernstein L.P. (2003-2004), Executive Vice President, Finance and Operations at AllianceBernstein L.P. (2000-2003), Senior Vice President, Finance and Administration at Sanford C. Bernstein & Co., Inc. (1998-2000), held various Executive positions at Fidelity Investments and at Citicorp, Director at Forest Laboratories, LLC (2011-2014), Director at Computershare Ltd. (2010-2012) and Director at AllianceBernstein L.P. (2004-2009). He holds a Bachelor of Business Administration degree from University of Connecticut.

Galia Maor

Ms. Galia Maor serves as Director at Teva Pharmaceutical Industries Limited since 2012. Her work experience includes the following roles: President and Chief Executive Officer at Bank Leumi Le Israel B.M. (May 1, 1991-April 30, 2012) and Director at Strauss Group Ltd. Having held senior positions in the Bank of Israel and in the Israeli banking system, Ms. Maor possesses extensive managerial and financial experience in the Israeli and world economy and she is a prominent public figure in a large number of academic, social and international economic organizations. Ms. Maor holds a Bachelors degree in Economics and Statistics and a MBA degree, both from The Hebrew University of Jerusalem. Ms. Maor holds Honorary Doctorates from the Technion-Israel Institute of Technology, Ben Gurion University and Bar Ilan University.

Ory Slonim

Mr. Ory Slonim serves as Director at Teva Pharmaceutical Industries Limited since 2008. His work experience includes the following roles: Statutory Independent Director at the Company (1998-2003), Attorney (since 1970), Director and Chairman of the audit committee at U. Dori Group Ltd. (1993-2011), Director at Oil Refineries Ltd.(2007-2012), Vice Chairman of Harel Insurance Investments and Financial Services Ltd. (2008-2013), Vice Chairman of the Board of Migdal Insurance and Financial Holdings Ltd. (1988-2007), Chairman of the Variety Club-Israel (since 2006), Chairman of the Ethics Tribunal of the Israeli Press Council (since 1994) and Lecturer at Tel Aviv University (Lahav Plan). Mr. Slonim received the Presidential Volunteer Medal in 1992 and the Presidential Medal of Distinction in 2012. He holds a LLB degree from The Hebrew University of Jerusalem.

Jean-Michel Halfon

Mr. Jean-Michel Halfon serves as Statutory-Independent Director at Teva Pharmaceutical Industries Limited since 2014. His work experience includes the following roles: Independent Consultant, providing consulting services to pharmaceutical, distribution, healthcare IT and R&D companies, President and General Manager of Emerging Markets at Pfizer Inc. (2008-2010) and Director of Marketing in France for Merck & Co. (1987-1989). Mr. Halfon holds a Bachelor of Science degree from Ecole Centrale des Arts et Manufactures and a MBA degree from Ecole Supérieur des Affaires (ESA).

Joseph Nitzani

Mr. Joseph Nitzani serves as Statutory Independent Director at Teva Pharmaceutical Industries Limited since September 2008. His work experience includes the following roles: Chairman of Hadassah Medical Center (2008-2010), Director at Hadassah Medical Center (1996-2008), Head of the Client Assets Private Banking and Consulting Division at Mizrahi-Tefahot Bank Ltd, Managing Director of the Government Companies Authority (1991-1995), Chief Executive Officer at the Tel-Aviv Stock Exchange (1980-1991), Director in three subsidiaries of Migdal Capital Markets Group (December 2009-2013), Chairman at a subsidiary of Migdal Capital Markets Group (2010-2013), Director at the Tel-Aviv Stock Exchange and at S&P Maalot (both 2001-2007), Director at Adanim Mortgage Bank (2006-2008) and Chairman of the endowment fund and Member of the investment funds committee of Tel Aviv University (since 2012). He holds a Bachelor of Arts degree in Economics from Bar-Ilan University and a MBA degree from Tel Aviv University.

Gabrielle Sulzberger

Ms. Gabrielle Sulzberger serves as Statutory Independent Director at Teva Pharmaceutical Industries Limited since September 2015. Her work experience includes the following roles: General Partner and Investment Manager of Rustic Canyon/Fontis Partners, L.P. (since October 2005), Director at Whole Foods Market, Inc. (since 2003) where she chairs the audit committee, Director at Brixmor Property Group (since 2015), Director at Stage Stores, Inc. (2010-2015), Chief Financial Officer at several privately owned companies and Principal at several private equity capital funds. She holds a Bachelors degree in Urban Studies from Princeton University, a Juris Doctor degree from Harvard School of Law and a MBA degree from Harvard Business School.

Kevin Mannix